A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Inclusion Criteria:

• Has histologically confirmed epithelial ovarian, fallopian tube, or primaryperitoneal carcinoma.

• Has received 4 or more cycles of platinum-based doublet chemotherapy in first-lineand a total of 6 cycles of carboplatin-based doublet chemotherapy in second-linesetting for ovarian cancer (OC).

• Has platinum-sensitive epithelial OC,

• Has provided tissue of a tumor lesion that was not previously irradiated

• Human immunodeficiency virus (HIV)-infected participants must have well controlledHIV on antiretroviral therapy

• Participants who are hepatitis B surface antigen positive are eligible if they havereceived hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and haveundetectable HBV viral load prior to allocation (Part 1) or randomization (Part 2)

• Participants with a history of hepatitis C virus (HCV) infection are eligible if HCVviral load is undetectable at screening

• Has an ECOG performance status of 0 to 1 assessed within 7 days before allocation (Part 1) or randomization (Part 2)

Exclusion Criteria:

• Has nonepithelial cancers (germ cell tumors and sex cord-stromal tumors), borderlinetumors (low malignant potential), mucinous, seromucinous that is predominantlymucinous, malignant Brenner's tumor and undifferentiated carcinoma

• Has platinum-resistant OC or platinum-refractory OC

• Has history of documented severe dry eye syndrome, severe Meibomian gland diseaseand/or blepharitis, or severe corneal disease that prevents/delays corneal healing.

• Has active inflammatory bowel disease requiring immunosuppressive medication orprevious history of inflammatory bowel disease (e.g. Crohn's disease, ulcerativecolitis, or chronic diarrhea)

• Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.

• Has a history of (noninfectious) pneumonitis/interstitial lung disease that requiredsteroids or has current pneumonitis/interstitial lung disease.

• HIV-infected participants with a history of Kaposi's sarcoma and/or MulticentricCastleman's Disease

• Has received more than 2 prior lines of systemic therapy for OC.

• Has received prior systemic anticancer therapy within 3 weeks or 5 half-lives (whichever is shorter) before allocation (Part 1) or randomization (Part 2)

• Has received prior radiotherapy within 2 weeks of allocation (Part 1) orrandomization (Part 2), or has radiation related toxicities, requiringcorticosteroids

• Has an additional malignancy that is progressing or has required active treatmentwithin the past 3 years

• Has active central nervous system (CNS) metastases and/or carcinomatous meningitis

• Has an active infection requiring systemic therapy